US equities |
NVDA $240.16 ▲+0.53% SPCX $172.85 ▲+1.03% MU $1,063.88 ▼-0.01% MRVL $289.25 ▲+6.64% AMD $654.83 ▲+3.65% INTC $114.93 ▼-1.08% AVGO $379.05 ▲+4.56% TSLA $380.31 ▲+0.42%
FinancialContent

Vericel Corporation - Common Stock (NQ:VCEL)

40.52 -0.55 (-1.34%)
Delayed Quote Updated: 2:15 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
HC Wainwright & Co. Maintains Buy Rating for Vericel: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Vericel Announces Preliminary Full-Year and Fourth Quarter 2023 Financial Results
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024
From Vericel Corporation
Via GlobeNewswire
News headline image
Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development ↗
Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S. 
Via Benzinga
News headline image
Analyst Ratings for Vericel ↗
 
Via Benzinga
News headline image
Analyst Ratings for Vericel ↗
 
Via Benzinga
News headline image
Expert Ratings for Vericel ↗
 
Via Benzinga
News headline image
3 Biotech Stocks That Could Boom or Bust by 2025 ↗
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday. 
Via InvestorPlace
News headline image
3 Strong Buy Stocks Set to Take Off in the Coming Months ↗
These 3 strong buy stocks have industry experts' positive outlook and seal of approval. The only question is, are you in? 
Via InvestorPlace
News headline image
Vericel Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Present at the Stephens Annual Investment Conference
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Vericel Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analyst Expectations for Vericel's Future ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 8, 2023 ↗
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Vericel to Report Third-Quarter 2023 Financial Results on November 8, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Announces U.S. Commercial Availability of NexoBrid® (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel's Short Report: Deep Dive Into Knee-Repair Focused Company's 27 Years of Losses ↗
J Capital Research has released a short idea report on Vericel Corporation (NASDAQ: 
Via Benzinga
News headline image
Vericel to Present at the Morgan Stanley Global Healthcare Conference
From Vericel Corporation
Via GlobeNewswire
News headline image
As America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs ↗
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to 80% of the population will experience back pain at some point. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗
 
Via Benzinga
News headline image
Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report Second-Quarter 2023 Financial Results on August 2, 2023
From Vericel Corporation
Via GlobeNewswire
Vericel Corp. (NASDAQ: VCEL) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Report First-Quarter 2023 Financial Results on May 10, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 7, 2023
From Vericel Corporation
Via GlobeNewswire
News headline image
Vericel Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Full-Year 2023 Financial Guidance
From Vericel Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >